TrialSignal transduction and targeted therapy2026

Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation.

Jiajun Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.